zintick

Kiniksa Pharmaceuticals International KNSA

Kiniksa Pharmaceuticals International, plc · Nasdaq · Pharmaceutical Preparations

$95.18+6.70%close on Oct. 28, 2026 · volume 1.7M · Yahoo Finance

Price, last 47 sessions

$80.00$90.00Sept. 2026Oct. 2026
Aug. 24, 2026 to Oct. 28, 2026 · high $95.18 · low $72.98 · SEC filing, placed when SEC released it

Our coverage

Nothing published yet.

Insider buying and selling

DateInsiderTradeSharesAvg. priceValue
Sept. 3, 2026Michael R. Megna
CHIEF ACCOUNTING OFFICER
Sold
10b5-1 plan
4,600$80.30$369,380
July 29, 2026G. Bradley Cole
director
Sold3,673$81.43$299,092

Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.

Recent SEC filings

All 15 →
  • 8-KOct. 27, 2026, 7:32 a.m. ETView on SEC.gov

    Results of operations and financial condition · Financial statements and exhibits

    AI summary, unreviewedKiniksa Pharmaceuticals Q3 2026 revenue of $286.0 million beats $260.6 million consensus, and ARCALYST 2026 guidance is raised to $1.045-$1.050 billion

  • 10-QOct. 27, 2026, 4:36 p.m. ETView on SEC.gov
  • 8-KOct. 22, 2026, 4:28 p.m. ETView on SEC.gov

    Departure/appointment of directors or officers

    AI summary, unreviewedKiniksa Pharmaceuticals promotes EVP and COO Ross Moat to President and Chief Operating Officer, with base salary raised to $700,000 and target bonus to 60%

  • 4Sept. 3, 2026, 4:41 p.m. ETView on SEC.gov
  • 4Sept. 3, 2026, 4:49 p.m. ETView on SEC.gov
  • 4Sept. 3, 2026, 4:43 p.m. ETView on SEC.gov
  • 4Sept. 3, 2026, 4:48 p.m. ETView on SEC.gov
  • 4Sept. 3, 2026, 4:46 p.m. ETView on SEC.gov